Skip to content

Life sciences and pharmaceuticals

Tackling complexity. Delivering precision.

Planning and precision are our specialities.

Highly controlled environments and facilities, like those needed for pharmaceutical, life science and research facilities, require exactly our aptitude for simplifying the complex.

We understand the unique environments in which life science and pharmaceutical organisations operate. We provide the expertise needed to realise their business objectives, from low value to hyper-scale turnkey solutions.

As a multi-disciplinary expert, we have the capabilities and experience to ensure pharmaceutical manufacturing plants, laboratories and research facilities meet both the ultra-specific needs of our clients and their staff. Our teams possess the knowledge to deliver carbon efficient facilities, leveraging innovative techniques and creative solutions.

Demand for production and research facilities is unwavering. We are relentlessly pursuing better ways to improve the design and flexibility of infrastructure to create adaptable research spaces that support groundbreaking scientific discoveries.

Prioritising operational readiness

A key part of our offering is an emphasis on supporting our clients in getting their facilities fully operational. We ensure readiness is a focus in all aspects of our roles from feasibility through to performance qualification.

By working in partnership, we accelerate return on investment. Ensuring client equipment integration into our design and delivery programmes allows facilities to be operationally ready on day one.

GMP and GLP experienced

‘Good Manufacturing Practices’ (GMP) and ‘Good Laboratory Practices’ (GLP) are strategic frameworks to drive performance and value optimisation beyond exacting compliance standards. To meet them while balancing sustainability, efficiency and cost requires skilled experts with aptitudes for tackling challenges and finding unique solutions.

This is who we are. Our foundations were built on the pursuit of a better way. And our life sciences and pharmaceutical delivery teams embody this. We’ve supported clients in meeting these standards again and again. We have the experience and the drive to navigate these technicalities while optimising programmes.

Contact us

Portrait of Gary Sweeney

Gary Sweeney

Director for Healthcare, Life Sciences and Technology, Europe

Portrait of Steve Bernstein

Steven Bernstein

Life Sciences Sector Lead, Americas

close up of person taking notes on a transparent wall panel

Unleash your potential

Bring your unique perspective to a career at Mace. Help us shape the cities of tomorrow.
Visit careers
Mace Logo

Mace Consult and Mace Group are now two independent businesses.

In 2025, a majority investment in Mace Consult by Private Equity at Goldman Sachs Alternatives was announced through a demerger from Mace Group.

This completed on 5 March 2026, with Mace Consult and Mace Group (which includes Mace Construct) now independent businesses. To continue, please choose whether you want to explore Mace Consult or Mace Construct.